Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, I	D.C.	20549	
---------------	------	-------	--

STATEMENT OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Haddadin Yezan Munther			2. Issuer Name and Ticker or Trading Symbol Outlook Therapeutics, Inc. [OTLK]									k all applic Directo	able) r	g Pers	son(s) to Iss	vner			
(Last)	•	irst) IERAPEUTICS,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/19/2020						Officer below)	(give title		Other (s below)	specify				
7 CLARKE DRIVE				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable							
(Street)	URY N	J	08512											Line) X		led by Mor		orting Perso I One Repo	- 1
(City)	(S	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date			2. Transad Date (Month/Da	Execution Date,		Code (Instr. 5)			4 and Securitie Beneficia		es Form ally (D) of Following (I) (II		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
							Code	v	Amount	(A) or (D)		се	Transact (Instr. 3 a	ction(s)			(1130.4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Perivative Security 3. Transaction Date Execution Date, if any (Month/Day/Year)		Co	ransaction of code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		5	Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Co	ode '	v	(A)	(D)	Date Exercisabl		expiration pate	Title	Amou or Numb of Share	per					
Stock Option (Right to Buy)	\$0.54	03/19/2020		1	A		15,000		(1)	0	3/19/2030	Common Stock	15,0	00	\$0.00	15,000	0	D	

Explanation of Responses:

1. The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 19, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Remarks:

/s/ Lawrence Kenyon, Attorney-in-Fact

** Signature of Reporting Person Date

03/20/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.